PORTFOLIO NEWS/ We’re pleased to announce our second exit in less than a year: Genfit has announced it will acquire Versantis. bit.ly/3QXJ0ru

PORTFOLIO NEWS/ We’re pleased to announce our second exit in less than a year: GENFIT has announced it will acquire Versantis expansion.com/catalunya/2022…

We present you the finalists for: 🏆 Seed-Stage: Finance Raise of the Year🏆 ⭐ AstriVax ⭐ EsoBiotec ⭐ Engimmune Therapeutics ⭐HAYA Therapeutics ⭐Homebiosciences ⭐Integra Therapeutics ⭐Adent Health ⭐Asgard Therapeutics ⭐Charco ⭐Relation Find out more: lsxleaders.com/lifestars-awar…

Congratulations to Integra Therapeutics and Sanifit (now CSL Vifor) for being selected finalists for the European Lifestars Awards Integra as Seed-Stage Finance Raise of the Year and Sanifit as M&A Deal for the Year. lsxleaders.com/lifestars-awar…

Corteria Pharmaceuticals strengthens its Executive Leadership Team, Board of Directors, and Scientific Advisory Board with Dr. Francesca Lawson, Dr. Marc Semigran and Dr. Jeffrey Testani. Welcome onboard! cutt.ly/HNtdNbp

ARTIFICIAL INTELLIGENCE + VENTURE CAPITAL/ I've been training AIA for the last four months. The time has come for her to pass "an exam" by being challenged by senior members of the team (Laura Rodríguez + Gemma Guinart ). Here's an abridged version of her interview. vimeo.com/782049018

JOB OPPORTUNITY: Our portfolio company Telomere Therapeutics is seeking candidates for a Project Manager position. cutt.ly/r29WFfu

(1/3) We are excited to announce the publication of preclinical results in Nature Biotechnology demonstrating that treatment using our engineered live biotherapeutic significantly reduced antibiotic-resistant Pseudomonas aeruginosa infections in mice: pulmobio.com/lastnews

(1/2) Our portfolio company Pulmobiotics SL has announced today the publication of preclinical results in Nature Biotechnology demonstrating the potential of engineered live biotherapeutics to reduce antibiotic-resistant infections in mice.

Engineered live bacteria suppress 𝘗𝘴𝘦𝘶𝘥𝘰𝘮𝘰𝘯𝘢𝘴 𝘢𝘦𝘳𝘶𝘨𝘪𝘯𝘰𝘴𝘢 infection in mouse lung and dissolve endotracheal-tube biofilms go.nature.com/3QTnJAZ

#JOB OPPORTUNITY: We’re seeking candidates with a strong scientific background and professional experience to join our team as Investment #Analyst. Apply now! bit.ly/3XA1GC4

Amazing opportunity to start a career in science as Industrial PhD! We look forward to expand our R&D team and deploy our gene writing platform for cell engineering #hiring

PORTFOLIO NEWS: Our portfolio company One Chain Immunotherapeutics receives 2.5M€ to develop a new #allogenic #CART treatment for T-ALL, by the European Innovation Council Transition program. x.com/onechaintx/sta…

Huge congratulations to Marc Güell, Founder our portfolio company Integra Therapeutics, for the Ángela Ruiz Robles Award for Young People in the field of #TechTransfer.

On Artificial Intelligence: 1/ While debating if AI is merely a "stochastic parrot" or possesses intelligence & potential consciousness (wrong debate), machines' capabilities increasingly resemble human abilities, profoundly disrupting society's fabric. I’m opening a thread:

EVENTS: Laura Rodríguez (Laura Rodríguez), Principal and Gemma Guinart (Gemma Guinart), Investment Associate at Invivo Capital are attending partnering in #BioequityEurope2023! Making new connections with the #Biotech community.

PORTFOLIO NEWS: We are excited to announce that our portfolio company, One Chain Immunotherapeutics, has raised €6.7M in a pre-Series A funding round. The round involved the participation of @InvivoCapital, @CDTI_innovacion, Nara Capital, Clave Capital, and the fcarreras.

GENE THERAPY FUTURE DIRECTIONS: A SIMPLE VISUAL FRAMEWORK TO UNDERSTAND HOW TO CAPTURE VALUE/ This quick_note highlights some of the principal trends in the sector affecting future value. It was co-authored with Gemma Guinart #quick_notes_LP

PORTFOLIO NEWS:  Invivo proudly announces an investment in EsoBiotec, a leader in in vivo engineered cell therapies for cancer. Very proud to join forces with UCB Ventures , @ThujaCapital, Sambrinvest, and WE (Wallonie Entreprendre). lnkd.in/dFFb_uqM

Lovely summary by Drs Luis Pareras and Cinta Díez at Invivo Partners in interesting strategies to bypass T cell dysfunction!!! Just amplifying their ideas/concepts of interest!!!